Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma

NCT ID: NCT04263935

Last Updated: 2025-04-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-03

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial is a prospective non-interventional observational study. The Chinese patients with lymphoma were included and the study data on driver gene abnormalities, demographic characteristics, clinicopathological characteristics and treatment were collected to evaluate the relevance of efficacy and disease prognosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma Gene Abnormality

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosed as lymphoma (according to WHO 2017 classification criteria)
2. Life expectancy no less than 3 months
3. Agreeing to sign the written informed consents

Exclusion Criteria

1. Other malignant tumor history or active malignant tumor need be treated
2. Researchers determine unsuited to participate in this trial
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Henan Cancer Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yanyan Liu

Director

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yanyan Liu, M.D. Ph.D

Role: STUDY_DIRECTOR

Henan Cancer Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university

Zhengzhou, Henan, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yanyan Liu, M.D. Ph.D

Role: CONTACT

+8613818176375

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yanyan Liu, M.D. Ph.D

Role: primary

+8613838176375

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HNCH2019341

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Analysis of Biomarkers in Lymph Node Tissue
NCT04228796 ACTIVE_NOT_RECRUITING